Pharmacobiology of topical Ankaferd hemostat in neoplastic disorders

Malkan, Umit Yavuz; Haznedaroglu, Ibrahim C.

doi:10.18621/eurj.1246824

Pharmacobiology of topical Ankaferd hemostat in neoplastic disorders

Ümit Yavuz Malkan, (Hacettepe Üniversitesi, Tıp Fakültesi, Hematoloji Anabilim Dalı, Ankara, Türkiye)

İbrahim Celalettin Haznedaroğlu (Hacettepe Üniversitesi, Tıp Fakültesi, Hematoloji Anabilim Dalı, Ankara, Türkiye)

The European Research Journal

14 4

Yıl: 2023 Cilt: 9 Sayı: 5 Sayfa Aralığı: 1271 - 1276 Metin Dili: İngilizce DOI: 10.18621/eurj.1246824 İndeks Tarihi: 06-09-2023

Pharmacobiology of topical Ankaferd hemostat in neoplastic disorders

Öz:

Ankaferd Hemostat (ABS) is a hemostatic agent of plant-extract acting on red blood cells used for achieving hemostasis. ABS has anti-inflammatory, anti-microbial, anti-fungal, anti-oxidative and anti-neoplastic effects. Cancer treatment is a challenging clinical condition that can lead to numerous clinical complications of different severity. Antineoplastic features of ABS had been depicted in many solid and hematological tumors. Supportive treatment of cancer is very important to decrease the mortality and morbidity of the cancer patients. ABS prevents and treats chemotherapy associated mucositis with its unique effects on the blood cells, endothelium, angiogenesis, cellular regeneration, wound healing and vascular dynamics. Those features of ABS bring it to be also beneficial for necrotizing enterocolitis as well. Besides its supportive and preventative roles in the cancer patients, ABS can also be potentially utilized as a chemoembolization agent within intratumoral treatment modality. The aim of this review is to summarize current pharmacobiology of topical ABS in neoplastic disorders.

Anahtar Kelime: Ankaferd hemostat neoplastic disorders pharmacobiology

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Bilgili H, Kosar A, Kurt M, Onal IK, Goker H, Captug O, et al. Hemostatic efficacy of Ankaferd Blood Stopper in a swine bleeding model. Med Princ Pract 2009;18:165-9.
2. Koçak E, Akbal E, Taş A, Köklü S, Karaca G, Can M, et al. Anti-inflammatory efficiency of Ankaferd blood stopper in experimental distal colitis model. Saudi J Gastroenterol 2013;19:126-30.
3. Saribas Z, Sener B, Haznedaroglu I, Hascelik G, Kirazli S, Goker H. Antimicrobial activity of Ankaferd Blood Stopper® against nosocomial bacterial pathogens. Open Med 2010;5:198-202.
4. Ciftci S, Keskin F, Keceli Ozcan S, Erdem MA, Cankaya B, Bingöl R, et al. In vitro antifungal activity of Ankaferd Blood Stopper against candida albicans. Curr Ther Res Clin Exp 2011;72:120-6.
5. Malkan UY, Haznedaroglu IC. Antineoplastic effects of Ankaferd hemostat. Biomed Res Int 2022;2022:2665903.
6. Bonnaure-Mallet M, Bunetel L, Tricot-Doleux S, Guérin J, Bergeron C, LeGall E. Oral complications during treatment of malignant diseases in childhood: effects of tooth brushing. Eur J Cancer 1998;34:1588-91.
7. da Cruz Campos MI, Neiva Campos C, Monteiro Aarestrup F, Vieira Aarestrup BJ. Oral mucositis in cancer treatment: natural history, prevention and treatment. Mol Clin Oncol 2014;2:337-40.
8. Atay MH, Arslan NA, Aktimur S, Buyukkaya P, Kelkitli E, Turgut M, et al. Safety and efficacy of ankaferd hemostat (ABS) in the chemotherapy-induced oral mucositis. Int J Hematol Oncol 2015;25:166-71.
9. Beyazit Y, Kekilli M, Haznedaroglu IC, Kayacetin E, Basaranoglu M. Ankaferd hemostat in the management of gastrointestinal hemorrhages. World J Gastroenterol 2011;17:3962-70.
10. Kurt M, Akdogan M, Onal IK, Kekilli M, Arhan M, Shorbagi A, et al. Endoscopic topical application of Ankaferd Blood Stopper for neoplastic gastrointestinal bleeding: a retrospective analysis. Digest Liver Dis 2010;42:196-9.
11. Haznedaroglu BZ, Beyazit Y, Walker SL, Haznedaroglu IC. Pleiotropic cellular, hemostatic, and biological actions of Ankaferd hemostat. Crit Rev Oncol Hematol 2012;83:21-34.
12. Metin B, Menevşe E, Sivrikaya A, Altınok T, Arıkoğlu H. The effects of ankaferd blood stopper on DNA damage and enzymes with paranchymal damaged rabbits. Med Sci 2017;6:5-10.
13. Uğur A, Sarac N, Cankal DA, Özle M. The antioxidant and antimutagenic activities of Ankaferd blood stopper, a natural hemostatic agent used in dentistry. Turk J Med Sci 2016;46:657-63.
14. Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R. Proteinase-activated receptors. Pharmacol Rev 2001;53:245-82.
15. López-Mateo I, Villaronga MA, Llanos S, Belandia B. The transcription factor CREBZF is a novel positive regulator of p53. Cell Cycle 2012;11:3887-95.
16. Walesky C, Apte U. Role of hepatocyte nuclear factor 4 alpha (HNF4α) in cell proliferation and cancer. Gene Expr 2015;16:101-8.
17. Wen D, Liu D, Tang J, Dong L, Liu Y, Tao Z, et al. Malic enzyme 1 induces epithelial–mesenchymal transition and indicates poor prognosis in hepatocellular carcinoma. Tumour Biol 2015;36:6211-21.
18. Ataman MB, Bucak MN, Çoyan K. Esterified glucomannan improves aflatoxin-induced damage of sperm parameters during liquid storage of ram semen at 5 C. Cryobiology 2014;68:405-10.
19. Yılmaz E, Güleç Ş, Torun D, Haznedaroğlu İC, Akar N. The effects of Ankaferd Blood Stopper on transcription factors in HUVEC and the erythrocyte protein profile. Turk J Haematol 2011;28:276-85.
20. Akalın I, Okur FV, Haznedaroglu IC, Sayınalp N, Aksu S, Buyukasık Y, et al. Acute in vitro effects of ABS (Ankaferd Hemostat) on the lymphoid neoplastic cells (B-CLL and RAJI tumor cell lines). Int J Hematol Oncol 2014;24:253-9.
21. Avcu F, Guner M, Misirci M, Elci P, Safali M, Goker H, et al. Evaluation of anti-neoplastic effects of a new hemostatic agent Ankaferd blood stopper on myeloma cell line and plasmocytoma development in Balb/c mice: results of the first in vitro and in vivo study. Blood 2014;124:5728
22. Kocyigit A, Guler EM, Haznedaroglu IC, Malkan UY. Ankaferd hemostat induces DNA damage, apoptosis and cytotoxic activity by generating reactive oxygen species in melanoma and normal cell lines. Int J Clin Exp Med 2017;10:2116-26.
23. Goker H, Cetinkaya D, Kilic E, Haznedaroglu I, Kirazli S, Firat H. Anti-cancer activity of ankaferd blood stopper on osteosarcom (SAOS-2) cell lines in vitro. Ankaferd: Scientific perspectives and basic-clinical data. Istanbul, Naviga Publications 2008;109.
24. Goker H, Kilic E, Cetinkaya D, Buyukasik Y, Aksu S et al. Anticancer activity of Ankaferd on human colon cancer (CACO2) in vitro. Ankaferd: Scientific perspectives and basic-clinical data. Istanbul, Naviga Publications 2008;108.
25. Sarı H, Çelik S, Çağlar F, Aktaş S, Bozkurt O, Yörükoğlu K, et al. A candidate antineoplastic herbal agent for bladder cancer: Ankaferd blood stopper. Int J Clin Pract 2021;75:e14789.
26. Fidan Ç. Ankaferd bloodstopper kanama durdurucunun in vitro meme kanseri hücrelerinin çoğalmaları üzerine olan etkisi. Trakya Üniversitesi Sağlık Bilimleri Enstitüsü, 2018.
27. Nenni M, Öncül S, Ercan A, Çelebier M, Süslü İ, Haznedaroğlu İC. Exposure of hepatocellular carcinoma cells to ankaferd blood stopper® alters cell death signaling networks confirmed by Oncoproteomic and genomic profiling studies. Curr Tradit Med 2021;7:246-58.
28. Ozle M, Uğar Çankal DA, Ilhan M, Keleş H, Küpeli Akkol E. Evaluation of the chemopreventive effects of Ankaferd Bloodstopper in 7, 12-dimethylbenz [a] anthracene-induced oral epithelial dysplasia. Clin Oral Investig 2018;22:3091-6.
29. Patıroğlu T, Şahin NE, Ünal E, Kendirci M, Karakükcü M, Özdemir MA. Effectiveness of ankaferd bloodstopper in prophylaxis and treatment of oral mucositis in childhood cancers evaluated with plasma citrulline levels. Turk J Heamatol 2018;35:85-6.
30. Buyuktiryaki M, Tayman C, Koyuncu I, Cakır U, Taskın Turkmenoglu T, Cakir E, et al. Therapeutic and preventative effects of ankaferd blood stopper in an experimental necrotizing enterocolitis model. Biomed Pharmacother 2019;110:105-10.
31. Koluman A, Akar N, Malkan UY, Haznedaroglu IC. Qualitative/chemical analyses of Ankaferd hemostat and its antioxidant content in synthetic gastric fluids. Biomed Res Int 2016;2016:8957820.
32. Dabak J, Gazuwa S, Ubom G. Hepatoprotective potential of calcium and magnesium against cadmium and lead induced hepatotoxicity in wistar rats. Asian J Biotechnol 2009;1:12-9.
33. Uboh FE, Ebong PE, Umoh IB. Comparative hepatoprotective effect of vitamins A and E against gasoline vapor toxicity in male and female rats. Gastroenterol Res 2009;2:295-302.
34. El Talees AA, Hussien NI, Allam MM, Mohammed DA. The potential effect of vitamin D on rats with fatty liver induced by a choline-deficient diet. Benha Med J 2018;35:67-73.
35. Sinbad OO, Folorunsho AA, Olabisi OL, Ayoola OA, Temitope EJ. Vitamins as antioxidants. J Food Sci Nutr Res 2019;2:214-35.
36. Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology 2016;64:106-16.
37. Tu J, Jia Z, Ying X, Zhang D, Li S, Tian F, et al. The incidence and outcome of major complication following conventional TAE/TACE for hepatocellular carcinoma. Medicine (Baltimore) 2016;95:e5606.
38. Muzykantov VR, Brenner JS. Vascular immunotargeting: take the highway to the first exit. Hepatology 2018;68:1672-4.
39. Ozbek O, Acar K, Koc O, Saritas K, Toy H, Solak Y, et al. Short-term effects of Ankaferd hemostat for renal artery embolization: an experimental study. Cardiovasc Interv Radiol 2013;36:498-504.
40. Koç O, Acar K, Özbek O, Güler İ, Sarıtaş K, Erdem TB, et al. Splenic artery embolization with Ankaferd blood stopper in a sheep model. Diagn Interv Radiol 2016;22:354-7.
41. Taş A, Köklü S, Beyazit Y, Karaca G, Astarcı HM, Akbal E, et al. Percutaneous ankaferd injection to in vivo liver tissue in comparison to ethanol in an experimental rat model. Clin Res Hepatol Gastroenterol 2011;35:549-53.

APA	Malkan U, Haznedaroglu I (2023). Pharmacobiology of topical Ankaferd hemostat in neoplastic disorders. , 1271 - 1276. 10.18621/eurj.1246824
Chicago	Malkan Umit Yavuz,Haznedaroglu Ibrahim C. Pharmacobiology of topical Ankaferd hemostat in neoplastic disorders. (2023): 1271 - 1276. 10.18621/eurj.1246824
MLA	Malkan Umit Yavuz,Haznedaroglu Ibrahim C. Pharmacobiology of topical Ankaferd hemostat in neoplastic disorders. , 2023, ss.1271 - 1276. 10.18621/eurj.1246824
AMA	Malkan U,Haznedaroglu I Pharmacobiology of topical Ankaferd hemostat in neoplastic disorders. . 2023; 1271 - 1276. 10.18621/eurj.1246824
Vancouver	Malkan U,Haznedaroglu I Pharmacobiology of topical Ankaferd hemostat in neoplastic disorders. . 2023; 1271 - 1276. 10.18621/eurj.1246824
IEEE	Malkan U,Haznedaroglu I "Pharmacobiology of topical Ankaferd hemostat in neoplastic disorders." , ss.1271 - 1276, 2023. 10.18621/eurj.1246824
ISNAD	Malkan, Umit Yavuz - Haznedaroglu, Ibrahim C.. "Pharmacobiology of topical Ankaferd hemostat in neoplastic disorders". (2023), 1271-1276. https://doi.org/10.18621/eurj.1246824

APA	Malkan U, Haznedaroglu I (2023). Pharmacobiology of topical Ankaferd hemostat in neoplastic disorders. The European Research Journal, 9(5), 1271 - 1276. 10.18621/eurj.1246824
Chicago	Malkan Umit Yavuz,Haznedaroglu Ibrahim C. Pharmacobiology of topical Ankaferd hemostat in neoplastic disorders. The European Research Journal 9, no.5 (2023): 1271 - 1276. 10.18621/eurj.1246824
MLA	Malkan Umit Yavuz,Haznedaroglu Ibrahim C. Pharmacobiology of topical Ankaferd hemostat in neoplastic disorders. The European Research Journal, vol.9, no.5, 2023, ss.1271 - 1276. 10.18621/eurj.1246824
AMA	Malkan U,Haznedaroglu I Pharmacobiology of topical Ankaferd hemostat in neoplastic disorders. The European Research Journal. 2023; 9(5): 1271 - 1276. 10.18621/eurj.1246824
Vancouver	Malkan U,Haznedaroglu I Pharmacobiology of topical Ankaferd hemostat in neoplastic disorders. The European Research Journal. 2023; 9(5): 1271 - 1276. 10.18621/eurj.1246824
IEEE	Malkan U,Haznedaroglu I "Pharmacobiology of topical Ankaferd hemostat in neoplastic disorders." The European Research Journal, 9, ss.1271 - 1276, 2023. 10.18621/eurj.1246824
ISNAD	Malkan, Umit Yavuz - Haznedaroglu, Ibrahim C.. "Pharmacobiology of topical Ankaferd hemostat in neoplastic disorders". The European Research Journal 9/5 (2023), 1271-1276. https://doi.org/10.18621/eurj.1246824